BARDA narrows Vaxart COVID vaccine pact; 5,000-subject follow-up continues

Vaxart, Inc.

Received Follow-Up Notice on Oct 8: BARDA intends to delimit Project Agreement excluding paused work.
Approximately 5,000 participants already enrolled in Phase 2b trial will continue to be followed.
Funding for follow-up of enrolled participants will continue; paused work no longer supported.
Company believes data from enrolled cohort will provide useful insights to advance COVID program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.